Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.68
+0.02000.43%
Post-market: 4.680.00000.00%19:38 EDT
Volume:475.31K
Turnover:2.24M
Market Cap:146.44M
PE:-1.13
High:4.81
Open:4.71
Low:4.67
Close:4.66
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.74
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.67
PE(LYR):-1.64

Loading ...

IMPACT Therapeutics Advances First PROTAC Candidate IMP2794 for KAT6A-Driven Cancers

TIPRANKS
·
Aug 12

JW Therapeutics Sets Board Meeting to Approve Interim 2026 Results

TIPRANKS
·
Aug 12

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Protara Therapeutics: Advancing Pipeline and Strong Cash Runway Underpin Boris Peaker’s Buy Rating and $25 Price Target

TIPRANKS
·
Aug 12

Lenz Therapeutics, Inc. : Leerink Partners Cuts Target Price to $10 from $20

THOMSON REUTERS
·
Aug 12

Alterity Therapeutics Secures New Patent for Oral Drug Candidate for Neurodegenerative Diseases; Shares Up 7%

MT Newswires Live
·
Aug 12

Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26

TIPRANKS
·
Aug 12

LENZ Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Tango Therapeutics Expands At-The-Market Equity Program

TIPRANKS
·
Aug 12

Mineralys Therapeutics Q2 Loss Widens

MT Newswires Live
·
Aug 12

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 12

Mineralys Therapeutics Appoints New Chief Medical Officer

TIPRANKS
·
Aug 12

LENZ Therapeutics Q2 Revenue Rises on VIZZ Sales

Reuters
·
Aug 12

Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate

Benzinga Earnings
·
Aug 12

Lenz Therapeutics Q2 Income from Operations USD -34.172 Million

THOMSON REUTERS
·
Aug 12

Press Release: LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Dow Jones
·
Aug 12

Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 12

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 12

Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate

Benzinga Earnings
·
Aug 12

Intensity Therapeutics price target lowered to $15 from $30 at Alliance Global

TIPRANKS
·
Aug 12